Ikeda Tsuyoshi
   Department   SOJO UNIVERSITY  Department of Pharmaceutical Sciences, FACULTY OF PHARMACEUTICAL SCIENCES
     /(DC)Division of Pharmaceutical Sciences,
Language English
Publication Date 2016/07
Peer Review Peer reviewed
Title Onionin A inhibits ovarian cancer progression by suppressing cancer cell proliferation and the protumour function of macrophages.
Contribution Type
Journal Scientific reports
Journal TypeAnother Country
Volume, Issue, Page 6,pp.29588
Author and coauthor Tsuboki Junko, Fujiwara Yukio, Horlad Hasita, Shiraishi Daisuke, Nohara Toshihiro, Tayama Shingo, Motohara Takeshi, Saito Yoichi, Ikeda Tsuyoshi, Takaishi Kiyomi, Tashiro Hironori, Yonemoto Yukihiro, Katabuchi Hidetaka, Takeya Motohiro, Komohara Yoshihiro
Details In the present study, we investigated whether ONA had a therapeutic anti-ovarian cancer effect using in vitro and in vivo studies. We found that ONA reduced the extent of ovarian cancer cell proliferation induced by co-culture with human macrophages. In addition, we also found that ONA directly suppressed cancer cell proliferation. A combinatorial effect with ONA and anti-cancer drugs was also observed. The activation of signal transducer and activator of transcription 3 (STAT3), which is involved in cell proliferation and chemo-resistance, was significantly abrogated by ONA in ovarian cancer cells. Furthermore, the administration of ONA suppressed cancer progression and prolonged the survival time in a murine ovarian cancer model under single and combined treatment conditions. Thus, ONA is considered useful for the additional treatment of patients with ovarian cancer owing to its suppression of the protumour activation of TAMs and direct cytotoxicity against cancer cells.
DOI 10.1038/srep29588
ISSN 2045-2322
PMID 27404320